VentriPoint Diagnostics

VentriPoint Diagnostics Inventory

Inventory of VentriPoint Diagnostics (VPT.V) as of Nov 2, 2026.

Inventory

0.00CAD

Last updated:

Inventory of VentriPoint Diagnostics is 2020 0.00 CAD. Inventory of VentriPoint Diagnostics was 2019 30,828.00 CAD. It decreases by % lower compared to the previous year.

The VentriPoint Diagnostics Inventory history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Inventory
Date
Inventory
Jan 1, 2014
63,457.00 CAD
Jan 1, 2015
64.54 CAD
Jan 1, 2016
11,968.00 CAD
Jan 1, 2017
50,582.00 CAD
Jan 1, 2018
68,990.00 CAD
Jan 1, 2019
30,828.00 CAD
Jan 1, 2020
0.00 CAD
The VentriPoint Diagnostics Inventory history
YEARInventoryYoY
0.00CAD-100.00%
30,828.00CAD-55.32%
68,990.00CAD+36.39%
50,582.00CAD+322.64%
11,968.00CAD+18,443.54%
64.54CAD-99.90%
63,457.00CAD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

VentriPoint Diagnostics Stock analysis

What does VentriPoint Diagnostics do? VentriPoint Diagnostics Ltd. develops and commercializes diagnostic tools for heart disease monitoring, focusing on the VentriPoint Medical System (VMS+). The VMS+ uses proprietary Knowledge Based Reconstruction (KBR) technology to create 3D heart models from ultrasound, providing volume and ejection fraction measurements comparable to MRI without requiring MRI scans. The company targets healthcare providers seeking point-of-care solutions for cardiac diagnostics, particularly in cardiology departments and clinics managing heart disease patients. Its applications cover congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, imaging, and cardiotoxicity in oncology patients. The company's products are sold to hospitals and medical facilities that require advanced cardiac imaging tools. VMS+ serves as a diagnostic aid that enhances ultrasound capabilities, eliminating the need for MRI in certain scenarios. The system's ability to visualize all four heart chambers and deliver MRI-equivalent metrics positions it as a cost-effective alternative for institutions aiming to reduce MRI dependency. VentriPoint Diagnostics Ltd. focuses on commercializing these diagnostic tools for heart disease monitoring across multiple clinical segments including cardiology, obstetrics, and oncology support services. VentriPoint Diagnostics Ltd. generates revenue through the sale of its diagnostic tools, specifically the VentriPoint Medical System (VMS+), to healthcare institutions. The VMS+ system is marketed as a point-of-care solution that improves cardiac diagnostics without MRI dependency. Its applications span various heart disease contexts, including congenital conditions, pregnancy-related cardiac monitoring, pulmonary hypertension, and oncology-related cardiotoxicity. The company's commercial strategy centers on providing MRI-equivalent diagnostic capabilities through ultrasound enhancement, targeting medical facilities seeking efficient and accessible cardiac imaging solutions. VentriPoint Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about VentriPoint Diagnostics stock

On Eulerpool you can find the complete historical development of Inventory VentriPoint Diagnostics since 2006 – with annual values, charts, and detailed analysis.

Inventory includes raw materials, work-in-progress, and finished goods. Efficient inventory management is crucial for profitability.

Inventory's CAD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Inventory's VentriPoint Diagnostics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — VentriPoint Diagnostics

All Key Metrics — VentriPoint Diagnostics